Holen Sie sich die Stockscreener-App
22.92
0.61%
0.14
Vorhandelsmarkt:
22.92
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
FIRDAPSE now available in Japan for muscle weakness - MSN
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - The Manila Times
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in December - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
JPMorgan Chase & Co. Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to "Buy" at StockNews.com - MarketBeat
HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price - MarketBeat
Catalyst Settles Patent Fight Against Teva Over Firdapse - Law360
Catalyst Pharmaceuticals' (CPRX) "Buy" Rating Reiterated at Bank of America - MarketBeat
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical - Yahoo Finance
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% HigherWhat's Next? - MarketBeat
Catalyst Pharma Gains, Teva Patent Settlement Seen Positive (1) - Bloomberg Law
Catalyst stock climbs 15% on Firdapse litigation settlement - Seeking Alpha
Catalyst Pharmaceuticals Reaches Settlement With Teva in Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Reaches Settlement Deal With Teva Over Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva - MarketWatch
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals - The Manila Times
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva - TipRanks
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® - GlobeNewswire
Catalyst Pharmaceuticals' (NASDAQ:CPRX) earnings growth rate lags the 37% CAGR delivered to shareholders - Simply Wall St
Oliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Interesting CPRX Call Options For January 17th - Nasdaq
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to "Strong-Buy" Rating - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
(CPRX) Long Term Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Sells 63,273 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Sanctuary Advisors LLC Acquires Shares of 31,040 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Buy at StockNews.com - MarketBeat
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - MSN
(CPRX) Investment Analysis and Advice - Stock Traders Daily
Is Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024? - Insider Monkey
Geode Capital Management LLC Sells 34,189 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Barclays PLC - MarketBeat
Wellington Management Group LLP Purchases Shares of 59,584 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease - Simply Wall St
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Large Increase in Short Interest - MarketBeat
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):